Trials / Unknown
UnknownNCT01630863
The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Yeungnam University College of Medicine · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To find the safe effective lowest light dose for photodynamic therapy (PDT). in the treatment of central serous chorioretinopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Photodynamic therapy | Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA. |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2014-10-01
- Completion
- 2015-03-01
- First posted
- 2012-06-28
- Last updated
- 2015-02-16
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01630863. Inclusion in this directory is not an endorsement.